Quotient Limited Revenue and Competitors
Estimated Revenue & Valuation
- Quotient Limited's estimated annual revenue is currently $98.9M per year.
- Quotient Limited received $5.0M in venture funding in February 2013.
- Quotient Limited's estimated revenue per employee is $292,586
- Quotient Limited's total funding is $284.3M.
Employee Data
- Quotient Limited has 338 Employees.
- Quotient Limited grew their employee count by -17% last year.
Quotient Limited's People
Name | Title | Email/Phone |
---|---|---|
1 | CFO | Reveal Email/Phone |
2 | Chief Strategy and Business Development Officer (NASDAQ:QTNT) | Reveal Email/Phone |
3 | CEO | Reveal Email/Phone |
4 | Head Group Accounting and Consolidation | Reveal Email/Phone |
5 | Head Human Resources | Reveal Email/Phone |
6 | Head Asia Pacific Region | Reveal Email/Phone |
7 | Head Systems R&D | Reveal Email/Phone |
8 | Head Supply Chain | Reveal Email/Phone |
9 | VP Product Development | Reveal Email/Phone |
10 | Head Site and Manufacturing | Reveal Email/Phone |
Quotient Limited Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $2.4M | 19 | -65% | N/A | N/A |
What Is Quotient Limited?
Quotient is a commercial-stage diagnostics company committed to increasing efficiencies and improving patient care through the provision of innovative tests within established markets. With an initial focus on blood grouping and donor disease screening(transfusion diagnostics), Quotient is developing MosaiQ, its next generation automation platform to address the comprehensive needs of the global transfusion diagnostics market. Once approved for sale, MosaiQ will be the first fully automated solution for blood grouping, quickly and comprehensively characterizing both donor and patient blood, improving patient outcomes and eliminating the need for expensive and time-consuming manual testing. MosaiQ will also undertake all mandated serological disease screening tests required for donor blood. Quotient has over 30 years of experience developing, manufacturing and commercializing transfusion diagnostic products. The company's operations are based in Switzerland, Scotland and the US. There are a wide variety of career opportunities at Quotient in various professional disciplines, such as Research and Development, Manufacturing, Quality, Commercial and Corporate Support functions. Joining Quotient is an opportunity to become part of a team which will shape the future of the company to achieve our Mission in Transforming Transfusion Diagnostics. If you are thinking about taking the next step in your career, then Quotient could be the place for you !!
keywords:Biotechnology,Energy,Hardware,Hardware Peripherals,Healthcare,Medical Devices,Medical Diagnostics,Pharmaceuticals$284.3M
Total Funding
338
Number of Employees
$98.9M
Revenue (est)
-17%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Quotient Limited News
JERSEY, Channel Islands, April 26, 2022 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ: QTNT), a commercial-stage diagnostics company,...
Quotient Limited Announces Appointment of New Board Member ... Channel Islands, April 26, 2022 (GLOBE NEWSWIRE) -- Quotient Limited ( QTNT),...
According to Zacks, Quotient Limited is a commercial-stage transfusion diagnostics company. It is focused on supplying blood-grouping...
Transaction proceeds will be used to fund the further development of the MosaiQ platform beyond the Donor Lab and the commercial launch of MosaiQ JERSEY, Channel Islands, May 24, 2021 (GLOBE NEWSWIRE) -- Quotient Limited ("Quotient") (NASDAQ: QTNT), a commercial-stage diagnostics company, today ...
Quotient Biodiagnostics, a global transfusion diagnostics group, Raised an additional $5.0m in equity funding. Backers included Galen Partners and Paul Cowan, CEO and founding shareholder in Quotient. The company intends to use the funding to continue development of its automation platform for ...
Quotient Limited Funding
Date | Amount | Round | Lead Investors | Reference |
---|---|---|---|---|
2012-03-07 | $11.2M | Undisclosed | Galen Partners | Article |
2012-03-07 | $11.2M | Undisclosed | Galen Partners | Article |
2013-02-28 | $5.0M | Undisclosed | Article |